Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

Human NSCLCs with activating mutations in EGFR frequently respond to treatment with EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib but responses are not durable as tumors acquire resistance. Secondary mutations in EGFR (T790M) or upregulation of the MET kinase are found in over 50% of resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhenfeng, Lee, Jae Cheol, Lin, Luping, Olivas, Victor, Au, Valerie, LaFramboise, Thomas, Abdel-Rahman, Mohamed, Wang, Xiaoqi, Levine, Alan D., Rho, Jin Kyung, Choi, Yun Jung, Choi, Chang-Min, Kim, Sang-We, Jang, Se Jin, Park, Young Soo, Kim, Woo Sung, Lee, Dae Ho, Lee, Jung-Shin, Miller, Vincent A., Arcila, Maria, Ladanyi, Marc, Moonsamy, Philicia, Sawyers, Charles, Boggon, Titus J., Ma, Patrick C., Costa, Carlota, Taron, Miquel, Rosell, Rafael, Halmos, Balazs, Bivona, Trever G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408577/
https://www.ncbi.nlm.nih.gov/pubmed/22751098
http://dx.doi.org/10.1038/ng.2330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408577/
https://www.ncbi.nlm.nih.gov/pubmed/22751098
http://dx.doi.org/10.1038/ng.2330

Ejemplares similares